RAD140 – (1182367-47-0)

Vosilasarm, also known by the development code RAD140 is a selective androgen receptor modulator (SARM) currently under development for the treatment of hormone-sensitive breast cancer. Specifically, it targets androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. Vosilasarm was initially developed by Radius Health and is now being developed by Ellipses Pharma.

In terms of pharmacology, Vosilasarm is a nonsteroidal SARM that acts as an agonist of the androgen receptor (AR). In preclinical studies, Vosilasarm has shown potent agonistic and anabolic effects in muscle and breast tissue, while exhibiting partial agonist or antagonist effects in the prostate gland and seminal vesicles. This selective activity suggests a potential for minimizing unwanted side effects associated with traditional androgen therapies.

Vosilasarm has also been investigated for other potential applications, such as treating sarcopenia, osteoporosis, and cancer cachexia-related weight loss, although development for these indications has been discontinued. As of March 2023, Vosilasarm is in phase 1/2 clinical trials for the treatment of breast cancer.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Vosilasarm
https://www.medchemexpress.com/RAD140.html
https://www.medkoo.com/products/16060
https://www.sciencedirect.com/science/article/pii/S266608492400216X